bioAffinity Technologies, Inc. (NASDAQ:BIAF) Short Interest Down 43.3% in December

bioAffinity Technologies, Inc. (NASDAQ:BIAF) saw a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling 31,376 shares, a decrease of 43.3% from the November 30th total of 55,359 shares. Currently, 0.7% of the company’s shares are short sold. Based on an average trading volume of 79,398 shares, the days-to-cover ratio is presently 0.4 days. Based on an average trading volume of 79,398 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.7% of the company’s shares are short sold.

bioAffinity Technologies Price Performance

Shares of BIAF stock opened at $1.17 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.65. bioAffinity Technologies has a fifty-two week low of $1.13 and a fifty-two week high of $46.53. The firm has a market cap of $5.27 million, a P/E ratio of -0.06 and a beta of 2.41. The business’s 50 day moving average price is $1.80 and its 200-day moving average price is $5.33.

bioAffinity Technologies (NASDAQ:BIAF) last announced its quarterly earnings results on Friday, November 14th. The company reported ($2.70) EPS for the quarter, hitting analysts’ consensus estimates of ($2.70). The company had revenue of $1.45 million during the quarter, compared to analyst estimates of $1.41 million. bioAffinity Technologies had a negative return on equity of 425.87% and a negative net margin of 217.45%.

Hedge Funds Weigh In On bioAffinity Technologies

A hedge fund recently bought a new stake in bioAffinity Technologies stock. Scientech Research LLC acquired a new position in bioAffinity Technologies, Inc. (NASDAQ:BIAF) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 16,583 shares of the company’s stock, valued at approximately $49,000. Scientech Research LLC owned 0.46% of bioAffinity Technologies at the end of the most recent reporting period. 1.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Wall Street Zen downgraded bioAffinity Technologies to a “strong sell” rating in a research report on Saturday, September 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of bioAffinity Technologies in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce”.

About bioAffinity Technologies

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.